Extensive-stage small-cell lung cancer: first-line and second-line treatment options
J Zugazagoitia, L Paz-Ares - Journal of Clinical Oncology, 2022 - ascopubs.org
Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more
than two decades without clinical progress, the addition of programmed cell death protein 1 …
than two decades without clinical progress, the addition of programmed cell death protein 1 …
Relapsed small cell lung cancer: treatment options and latest developments
N Asai, Y Ohkuni, N Kaneko… - … advances in medical …, 2014 - journals.sagepub.com
According to recent analyses, there was a modest yet significant improvement in median
survival time and 5-year survival rate of limited stage small cell lung cancer (SCLC) in North …
survival time and 5-year survival rate of limited stage small cell lung cancer (SCLC) in North …
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer
J von Pawel, R Jotte, DR Spigel… - Journal of clinical …, 2014 - ascopubs.org
Purpose Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor,
showed promising activity in small-cell lung cancer (SCLC) in phase II trials. This phase III …
showed promising activity in small-cell lung cancer (SCLC) in phase II trials. This phase III …
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
Objective Patients with etoposide/platinum-refractory extensive disease (ED) small-cell lung
cancer (SCLC) have a dismal prognosis. We aimed to evaluate the efficacy and safety of …
cancer (SCLC) have a dismal prognosis. We aimed to evaluate the efficacy and safety of …
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
H Imai, Y Nagai, H Minemura, T Tsuda… - Investigational New …, 2022 - Springer
This study examined the activity and safety of amrubicin monotherapy among relapsed small-
cell lung cancer (SCLC) patients who had previously been treated with atezolizumab plus …
cell lung cancer (SCLC) patients who had previously been treated with atezolizumab plus …
Reconsidering the cutoff value for sensitive and refractory relapses in extensive-stage SCLC in the era of immunotherapy
M Torasawa, H Horinouchi, S Nomura, S Igawa… - Journal of Thoracic …, 2024 - Elsevier
Introduction Traditionally, relapsed SCLC has been classified as “sensitive” or “refractory” on
the basis of cutoff values (60 or 90 d) for the duration between the last chemotherapy and …
the basis of cutoff values (60 or 90 d) for the duration between the last chemotherapy and …
Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients
N Horita, M Yamamoto, T Sato, T Tsukahara… - Scientific reports, 2016 - nature.com
Currently, amrubicin is permitted for relapsed small-cell lung carcinoma (SCLC) only in
Japan. The efficacy and adverse effects of amrubicin as reported by previous studies varied …
Japan. The efficacy and adverse effects of amrubicin as reported by previous studies varied …
Second-line chemotherapy for small-cell lung cancer (SCLC)
YH Kim, M Mishima - Cancer treatment reviews, 2011 - Elsevier
Although small-cell lung cancer (SCLC) generally shows an excellent response to initial
chemotherapy, most patients finally relapse and salvage chemotherapy is considered …
chemotherapy, most patients finally relapse and salvage chemotherapy is considered …
Novel cytotoxic chemotherapies in small cell lung carcinoma
D Cortinovis, P Bidoli, S Canova, F Colonese… - Cancers, 2021 - mdpi.com
Simple Summary Small cell lung cancer is a subtype of lung cancer and one of the deadliest
thoracic tumours. Historically, chemotherapy consisting of either platinum plus etoposide or …
thoracic tumours. Historically, chemotherapy consisting of either platinum plus etoposide or …
[HTML][HTML] A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer
H Yoshioka, N Katakami, H Okamoto, Y Iwamoto… - Annals of …, 2017 - Elsevier
Background Amrubicin is approved for treating non-small-cell lung cancer (NSCLC) and
small-cell lung cancer. However, no direct comparisons between amrubicin and docetaxel, a …
small-cell lung cancer. However, no direct comparisons between amrubicin and docetaxel, a …